Riken Genesis and Burning Rock Biotech (BNR) announced that the OncoGuide OncoScreen Plus CDx System based on OncoScreen Plus to be used as a companion diagnostic for AstraZeneca’s (AZN) capivasertib has received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNR: